<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072797</url>
  </required_header>
  <id_info>
    <org_study_id>2016BJYYEC-121-02</org_study_id>
    <nct_id>NCT03072797</nct_id>
  </id_info>
  <brief_title>Beijing Hospital Atherosclerosis Study</brief_title>
  <acronym>BHAS</acronym>
  <official_title>Beijing Hospital Atherosclerosis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Beijing Hospital Atherosclerosis Study (BHAS) is a prospective, single-center,
      observational cohort study performed at the Beijing Hospital in Beijing, China. Subjects
      enrolled in this study will be the consecutive patients undergoing coronary angiography in
      the hospital. Blood samples are taken immediately before the angiographic procedure. Clinical
      and angiographic characteristics are recorded. All patients will have routine follow-up at 6
      months and 1 year postprocedure, then yearly thereafter. Follow-up includes mortality,
      myocardial infarction (MI), stroke, rehospitalization, coronary revascularization procedures,
      life styles, and medication use. The primary end point for the study will be the major
      adverse cardiovascular events (MACE), defined as death from any cause, nonfatal myocardial
      infarction, nonfatal stroke and revascularization. This study has been reviewed and approved
      by the Ethics Committee of Beijing Hospital. All enrolled individuals will be received
      written notice of the intended use of their blood samples and provided written consent.

      The major objectives of the BHAS Study are to (1) establish a prospective cohort and a
      biological sample bank in ethnic Chinese with coronary angiography, (2) identify baseline new
      biosignature profiles such as novel biomarkers via metabolomics approach associated with the
      subsequent clinical events, (3) assess the use of molecular profiles from multiple platforms
      (eg, genomics, proteomics, and metabolomics) integrated with readily available clinical
      information for improved risk classification for cardiovascular events, and (4) provide
      clearer understanding of underlying disease processes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with major adverse cardiovascular events (MACE)</measure>
    <time_frame>3 years</time_frame>
    <description>MACE include death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with other atherosclerosis events</measure>
    <time_frame>3 years</time_frame>
    <description>Other atherosclerosis events include readmission for angin and transient ischemic attack.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Stroke</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, 10 mL (whole blood, plasma, serum)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects enrolled in this study will be the consecutive patients undergoing coronary
        angiography at the Beijing Hospital in Beijing, China.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18y

          -  Consent for the study

          -  Primary reason for catheterization is concern for ischemic heart disease

          -  Complete clinical and coronary angiogram data available

        Exclusion Criteria:

          -  Primary pulmonary hypertension or severe lung disease

          -  Cardiac transplantation

          -  Other solid organ transplant

          -  Peripheral vascular intervention only

          -  Right heart catheterization only

          -  Advanced heart failure

          -  Congenital heart disease

          -  Women who are pregnant or nursing, or preparing for pregnant during the study period

          -  Progressive fatal disease

          -  History of alcoholism or drug abuse

          -  Patients with mental illness and are being treated

          -  Patients are undergoing radiotherapy or chemotherapy

          -  Acute and chronic infectious diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fusui Ji, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Beijing Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wenxiang Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The MOH Key Laboratory of Geriatrics, Beijing Hospital, National Center of Gerontology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruiyue Yang, M.D.</last_name>
    <phone>+861058115049</phone>
    <email>yangruiyue4057@bjhmoh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenduo Zhang, M.D.</last_name>
    <phone>+861085136232</phone>
    <email>zhangwenduo3103@bjhmoh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bejing Hosptial</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruiyue Yang, M.D.</last_name>
      <phone>+861058115049</phone>
      <email>yangruiyue4057@bjhmoh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wenduo Zhang, M.D.</last_name>
      <phone>+861085136232</phone>
      <email>zhangwenduo3103@bjhmoh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Fusui Ji, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenxiang Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun Dong, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xue Yu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruiyue Yang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenduo Zhang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Siming Wang, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xinyue Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kip KE, Hollabaugh K, Marroquin OC, Williams DO. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. J Am Coll Cardiol. 2008 Feb 19;51(7):701-7. doi: 10.1016/j.jacc.2007.10.034. Review.</citation>
    <PMID>18279733</PMID>
  </reference>
  <reference>
    <citation>Ussher JR, Elmariah S, Gerszten RE, Dyck JR. The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. J Am Coll Cardiol. 2016 Dec 27;68(25):2850-2870. doi: 10.1016/j.jacc.2016.09.972. Review.</citation>
    <PMID>28007146</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Hospital</investigator_affiliation>
    <investigator_full_name>Fusui Ji, MD</investigator_full_name>
    <investigator_title>Director, Department of Gerontological Cardiology</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Longitudinal</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Coronary angiography</keyword>
  <keyword>Follow-up</keyword>
  <keyword>Metabolomics</keyword>
  <keyword>Risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

